Prelude Capital Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $426K | Buy |
809
+214
| +36% | +$120K | 0.03% | 594 |
|
|
2026
Q1 | $334K | Buy |
+595
| New | +$382K | 0.03% | 662 |
|
|
2025
Q2 | – | Sell |
-512
| Closed | -$215K | – | 1158 |
|
|
2025
Q1 | $215K | Sell |
512
-45
| -8% | -$19.5K | 0.02% | 899 |
|
|
2024
Q4 | $230K | Buy |
557
+127
| +30% | +$55.7K | 0.01% | 924 |
|
|
2024
Q3 | $217K | Sell |
430
-458
| -52% | -$222K | 0.01% | 1021 |
|
|
2024
Q2 | $433K | Sell |
888
-408
| -31% | -$205K | 0.03% | 606 |
|
|
2024
Q1 | $700K | Buy |
+1,296
| New | +$708K | 0.04% | 493 |
|
|
2023
Q4 | – | Sell |
-2,477
| Closed | -$1.08M | – | 1221 |
|
|
2023
Q3 | $1.08M | Buy |
2,477
+1,802
| +267% | +$899K | 0.07% | 291 |
|
|
2023
Q2 | $339K | Sell |
675
-66
| -9% | -$31.6K | 0.02% | 589 |
|
|
2023
Q1 | $371K | Sell |
741
-3,195
| -81% | -$1.53M | 0.02% | 570 |
|
|
2022
Q4 | $1.61M | Buy |
3,936
+2,750
| +232% | +$1.07M | 0.08% | 257 |
|
|
2022
Q3 | $386K | Buy |
+1,186
| New | +$436K | 0.01% | 760 |
|
|
2021
Q2 | – | Sell |
-581
| Closed | -$284K | – | 1789 |
|
|
2021
Q1 | $284K | Buy |
+581
| New | +$291K | 0.01% | 1180 |
|
|
2020
Q3 | – | Sell |
-1,709
| Closed | -$564K | – | 2065 |
|
|
2020
Q2 | $564K | Buy |
+1,709
| New | +$495K | 0.03% | 450 |
|
|
2019
Q4 | – | Sell |
-122
| Closed | -$33K | – | 2065 |
|
|
2019
Q3 | $33K | Buy |
122
+73
| +149% | +$20.3K | ﹤0.01% | 1290 |
|
|
2019
Q2 | $13K | Sell |
49
-88
| -64% | -$21.7K | ﹤0.01% | 1346 |
|
|
2019
Q1 | $31K | Sell |
137
-105
| -43% | -$21.7K | ﹤0.01% | 1244 |
|
|
2018
Q4 | $45K | Sell |
242
-2,249
| -90% | -$461K | ﹤0.01% | 1138 |
|
|
2018
Q3 | $622K | Buy |
2,491
+117
| +5% | +$28.4K | 0.04% | 476 |
|
|
2018
Q2 | $517K | Buy |
2,374
+1,623
| +216% | +$334K | 0.03% | 525 |
|
|
2018
Q1 | $144K | Buy |
751
+208
| +38% | +$38.4K | 0.01% | 770 |
|
|
2017
Q4 | $85K | Sell |
543
-368
| -40% | -$57.9K | 0.01% | 824 |
|
|
2017
Q3 | $142K | Sell |
911
-109
| -11% | -$17.2K | 0.01% | 757 |
|
|
2017
Q2 | $165K | Buy |
+1,020
| New | +$166K | 0.02% | 633 |
|
|
2017
Q1 | – | Sell |
-641
| Closed | -$75K | – | 1610 |
|
|
2016
Q4 | $75K | Buy |
+641
| New | +$73.1K | 0.01% | 922 |
|
|
2015
Q1 | – | Sell |
-780
| Closed | -$58K | – | 2037 |
|
|
2014
Q4 | $58K | Buy |
+780
| New | +$54.7K | 0.01% | 1191 |
|
Other funds holding IDXX
Prelude Capital Management's IDXX Position: Q2 2026 in Review
Prelude Capital Management increased its Idexx Laboratories (IDXX) stake by 36% in Q2 2026, buying an estimated $120K and bringing the position to 809 shares worth $426K. The position accounts for 0.03% of the portfolio, ranked #594.
Prelude Capital Management first reported a position in IDXX in Q4 2014 and has held it in 26 quarters since. The position peaked at $1.61M in Q4 2022. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Prelude Capital Management held 809 shares of Idexx Laboratories worth $426K as of Q2 2026.
- Prelude Capital Management bought 214 Idexx Laboratories shares in Q2 2026, an estimated $120K.
- Idexx Laboratories made up 0.03% of Prelude Capital Management's portfolio in Q2 2026, its #594 holding.
- Prelude Capital Management first reported a position in Idexx Laboratories in Q4 2014 and has held it in 26 quarters since.
- Prelude Capital Management's Idexx Laboratories position peaked at $1.61M in Q4 2022.
- 1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.